Companies in the News

Nutcracker Therapeutics Announces $60 Million Series B Financing

Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using its proprietary push-button “GMP-in-a-box” system Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced that it has raised $60 million in Series B financing led by ARCH Venture Partners with participation from other top healthcare investors, including

Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Tria

Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join Escient board of directors SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, Inc., an industry-leading company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the completion of a $77.5 millio